About ImmunityBio, Inc.
https://immunitybio.comImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.
CEO
Richard Gerald Adcock
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 123
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:27.66M
Value:$83.52M
BLACKROCK, INC.
Shares:19.81M
Value:$59.83M
JANE STREET GROUP, LLC
Shares:12.84M
Value:$38.76M
Summary
Showing Top 3 of 292
About ImmunityBio, Inc.
https://immunitybio.comImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $32.06M ▲ | $83.56M ▼ | $-67.25M ▲ | -209.77% ▲ | $-0.07 ▲ | $-35.77M ▲ |
| Q2-2025 | $26.43M ▲ | $97.57M ▲ | $-92.56M ▲ | -350.26% ▲ | $-0.1 ▲ | $-59.54M ▲ |
| Q1-2025 | $16.52M ▲ | $80.89M ▲ | $-129.65M ▼ | -784.92% ▼ | $-0.15 ▼ | $-97.21M ▼ |
| Q4-2024 | $7.55M ▲ | $76.95M ▼ | $-59.16M ▲ | -783.4% ▲ | $-0.08 ▲ | $-40.12M ▲ |
| Q3-2024 | $6.11M | $86.36M | $-85.73M | -1.4K% | $-0.12 | $-41.07M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $153.66M | $0 ▼ | $569.82M ▼ | $-569.82M ▲ |
| Q2-2025 | $153.66M ▲ | $402.08M ▲ | $971.89M ▲ | $-570.75M ▲ |
| Q1-2025 | $61.59M ▼ | $303.76M ▼ | $894.24M ▲ | $-591.43M ▼ |
| Q4-2024 | $149.81M ▲ | $382.93M ▲ | $871.06M ▼ | $-489.1M ▲ |
| Q3-2024 | $130.37M | $364.57M | $1.11B | $-745.15M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-67.25M ▲ | $-68.91M ▲ | $-181.36M ▼ | $173.52M ▲ | $-76.81M ▼ | $-68.91M ▲ |
| Q2-2025 | $-92.56M ▲ | $-79.75M ▲ | $-16.14M ▼ | $172.81M ▲ | $77M ▲ | $-80.83M ▲ |
| Q1-2025 | $-129.67M ▼ | $-85.91M ▼ | $4.13M ▼ | $-982K ▼ | $-82.77M ▼ | $-87.03M ▲ |
| Q4-2024 | $-59.18M ▲ | $-85.14M ▲ | $9.83M ▼ | $106.93M ▲ | $31.61M ▲ | $-87.25M ▲ |
| Q3-2024 | $-85.75M | $-98.76M | $65.03M | $15.58M | $-18.14M | $-101.56M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $10.00M ▲ | $20.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 Product and Service Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q1-2018 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Europe | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $20.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 San Diego California | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Richard Gerald Adcock
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 123
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:27.66M
Value:$83.52M
BLACKROCK, INC.
Shares:19.81M
Value:$59.83M
JANE STREET GROUP, LLC
Shares:12.84M
Value:$38.76M
Summary
Showing Top 3 of 292